Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 19/20 | 0.62 |
| ▸ | CXCR2 | P25025 | 17/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828010 | 1.00 | CX3CR1 (0.62) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL23828050 | 0.91 | CX3CR1 (0.58) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL21615496 | 0.91 | CX3CR1 (0.58) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL21615506 | 0.91 | CX3CR1 (0.76) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL23828076 | 0.91 | CX3CR1 (0.76) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL23828063 | 0.89 | CX3CR1 (0.75) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL31199049 | 0.89 | CX3CR1 (0.75) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL23828059 | 0.89 | CX3CR1 (0.75) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL23828060 | 0.89 | CX3CR1 (0.75) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL1588357 | 0.87 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2024-08-13 | — | — | US | claimed |
| EP-3818065-B1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2023-03-15 | — | — | EP | claimed |
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2024-08-13 | — | — | US | disclosed |
| EP-3818065-B1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2023-03-15 | — | — | EP | disclosed |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2022-05-24 | — | — | US | disclosed |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2022-05-24 | — | — | US | disclosed |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
| WO-2020008064-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.